Celgene’s cancer pill to increase global sales

Published: 2012-11-21 07:00:00
Updated: 2012-11-21 07:00:00
Celgene Corp. is increasing global sales for its best-selling cancer pill Revlimid (lenalidomide) on new data that may convince doctors to choose the drug as a first option.

Revlimid generated $970 million in sales last year as a back-up therapy for patients with multiple myeloma who don’t res...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.